ArticleJACC. Case reports2026
Glucocorticoid Therapy for Recurrent In-Stent Restenosis: A Prospective Explorative Case Series.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent in-stent restenosis (RISR) remains a therapeutic challenge when conventional treatments show limited efficacy. This case series evaluated a prednisone-based therapeutic strategy in patients with unexplained RISR.
methodsIn this single-center prospective case series, 6 patients with RISR were included after exclusion of procedural failure, neoatherosclerosis, and systemic vasculitis by intracoronary imaging and laboratory testing. All patients had failed repeated revascularization and optimal medical therapy. Oral prednisone (0.5 mg/kg/d) was initiated and tapered monthly by 5 mg/d until a maintenance dose of 5-10 mg/d was achieved alongside guideline-directed therapy.
resultsOver a median follow-up of 4-years, 5 patients remained free from in-stent restenosis recurrence during treatment. One exhibited persistent in-stent restenosis but eventually achieved lesion stabilization after escalation to combined immunosuppressive therapy. Imaging demonstrated fibrotic neointimal hyperplasia without lipid-rich features. No serious steroid-related adverse events were observed.
conclusionsPrednisone-based anti-inflammatory therapy may represent a potential strategy for the management of refractory RISR. TAKE-HOME MESSAGES: Refractory RISR may represent an under-recognized inflammatory vascular process rather than purely mechanical failure. In selected patients who have exhausted conventional revascularization strategies, systemic anti-inflammatory therapy may offer a viable therapeutic alternative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.